Cardiometabolic disorders such as obesity and diabetes are key modifiable risk factors for Alzheimer’s
disease and related dementias (ADRD). These disorders contribute to the development and progression of
ADRD by promoting brain atrophy, white matter changes, cerebrovascular damage, blood–brain barrier
dysfunction, and cognitive decline. As such, therapeutic strategies that improve metabolic function may offer
novel approaches to preserving cognitive function and reducing ADRD risk. This talk will focus on
pharmacological and non-pharmacological approaches to treat metabolic dysfunction and potential mechanisms
that may underlie their beneficial effects on brain health.